Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: Results of a phase II multicenter trial

Melanoma Research

Volumn 20, Issue 2, 2010, Pages 141-146

  Wierzbicka Hainaut, Ewa ^a   Sassolas, Bruno ^b   Mourey, Laurent ^c   Guillot, Bernard ^d   Bedane, Christophe ^e   Guillet, Gerard ^a   Tourani, Jean Marc ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

^c Institut Claudius Rigaud   (France)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Cisplatin; Metastatic melanoma; Phase II study; Temozolomide

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; GROWTH FACTOR; METHYLPREDNISOLONE; SEROTONIN 3 ANTAGONIST; STEROID; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; MALE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; SKIN METASTASIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 77949552641     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283350578     Document Type: Article

References (27)

1. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27:3-9
2. Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncology (Williston Park) 1995; 9:1149-1158. discussion 1163-1164, 1167-1168
3. Middleton MR, Lorigan P, Owen J, Ashcroft L, Lee SM, Harper P, Thatcher N. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000; 82:1158-1162
4. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000; 19:21-34
5. Ho RC. Medical management of stage IV malignant melanoma? Medical issues. Cancer 1995; 75:735-741
6. Raymond E, Izbicka E, Soda H, Gerson SL, Dugan M, Von Hoff DD. Activity of temozolomide against human tumor colony-forming units. Clin Cancer Res 1997; 3:1769-1774
7. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazo[ 5,1, d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47:5846-5852
8. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomised phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166
9. Wang L, Setlow RB. Inactivation of O6-alkylguanine-DNA alkyltransferase in HeLa cells by cisplatin. Carcinogenesis 1989; 10:1681-1684
10. Piccioni D, D'Atri S, Papa G, Caravita T, Franchi A, Bonmassar E, Graziani G. Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. J Chemother 1995; 7:224-228
11. Daponte A, Ascierto PA, Gravina A, Melucci M, Scala S, Ottiano A, et al. Temozolomide and cisplatin in avdanced malignant melanoma. Anticancer Res 2005; 25:1441-1447
12. Glover D, Glick JH, Weiler C, Fox K, Guerry D, Glover D. WR -2721 and high dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987; 5:574-578
13. Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR, Barrington R, et al. A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res 1999; 5:1629-1637
14. Therasse P, Arbuck SG, Eisenhauer EA,Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000; 92:205-216
15. http://ctep.info.nih.gov/protocolDevelopment/electronic-applications/ctc. htm
16. Bafaloukos D, Tsoutsos D, Kalofonos H, Chalkidou S, Panagiotou P, Linardou E, et al. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 2005; 16:950-957
17. Tsang LL, Quarterman CP, Gescher A, Slack JA. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother Pharmacol 1991; 27:342-346
18. Middleton MR, Lunn JM, Morris C, Rustin G, Wedge SR, Brampton MH, et al. O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 1998; 78:1199-1202
19. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994; 33:9045-9051
20. Belanich M, Randall T, Pastor MA, Kibitel JT, Alas LG, Dolan ME, et al. Intracellular localization and intercellular heterogeneity of the human DNA repair protein O6-methylguanine-DNA methyltransferase. Cancer Chemother Pharmacol 1996; 37:547-555
21. Liu Y, Vinje J, Pacifico C, Natile G, Sletten E. Formation of adenine-N3/ guanine-N7 cross-link in the reaction of trans-oriented platinum substrates with dinucleotides. J Am Chem Soc 2002; 124:12854-12862
22. Baer JC, Freeman AA, Newlands ES,Watson AJ, Rafferty JA, Margison GP. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 1993; 67:1299-1302
23. D'Atri S, Piccioni D, Castellano A, Tuorto V, Franchi A, Lu K, et al. Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann Oncol 1995; 6:389-393
24. Wedge SR, Porteus JK, May BL, Newlands ES. Potentiation of temozolomide and BCNU cytotoxicity by O6-benzylguanine: a comparative study in vitro. Br J Cancer 1996; 73:482-490
25. Taverna P, Catapano CV, Citti L, Bonfanti M, D'Incalci M. Influence of O6 methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethyl nitrosoureas. Anticancer Drugs 1992; 3:401-405
26. Tas F, Argon A, Camlica H, Topuz E. Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial. Melanoma Res 2005; 15:543-548
27. Paul MJ, Summers Y, Calvert AH, Rustin G, Brampton MH, Thatcher N, Middleton MR. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 2002; 12:175-178